About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(APPswe,PSEN1dE9)85Dbo
transgene insertion 85, David R Borchelt
MGI:3524957
Summary 18 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Agrntm1Rwb/Agrntm1Rwb
Tg(APPswe,PSEN1dE9)85Dbo/?
Tg(Tek-cre)1Ywa/?
involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * SJL MGI:5692156
cn2
Map2k4tm1Ctr/Map2k4tm1Ctr
Map2k7tm1Rjd/Map2k7tm1Rjd
Tg(APPswe,PSEN1dE9)85Dbo/0
Tg(Camk2a-cre/ERT2)2Gsc/0
involves: C3H * C57BL/6 * FVB/N MGI:5297909
cx3
Prnptm2Edin/Prnptm2Edin
Tg(APPswe,PSEN1dE9)85Dbo/0
B6.Cg-Prnptm2Edin Tg(APPswe,PSEN1dE9)85Dbo MGI:5050418
cx4
Hc1/Hc1
Tg(APPswe,PSEN1dE9)85Dbo/0
D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo MGI:5702670
cx5
Itm2btm1.1Ldad/Itm2b+
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129 * C3H * C57BL/6 MGI:3810993
cx6
Agrntm5Jrs/Agrntm5Jrs
Tg(APPswe,PSEN1dE9)85Dbo/?
involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * FVB/N MGI:5692159
cx7
Nr1h3tm1Djm/Nr1h3tm1Djm
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6 MGI:4359165
cx8
Nr1h2tm1Djm/Nr1h2tm1Djm
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6 MGI:4359167
cx9
Ptger2tm1Brey/Ptger2tm1Brey
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6 MGI:4834862
cx10
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pion)Pggd/Gt(ROSA)26Sor+
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6 MGI:5295743
cx11
Rtn4rl2tm1Yanr/Rtn4rl2tm1Yanr
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: 129S6/SvEvTac * C3H * C57BL/6 * C57BL/6J MGI:5292071
cx12
Tg(APPswe,PSEN1dE9)85Dbo/?
Tg(MGS1-19375/CFP)2R9Rwb/?
involves: C3H * C57BL/6 * C57BL/6J MGI:5692162
cx13
Leprdb/Lepr+
Tg(APPswe,PSEN1dE9)85Dbo/0
involves: C3H * C57BL/6 * C57BLKS/J MGI:5435319
tg14
Tg(APPswe,PSEN1dE9)85Dbo/0 B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax MGI:3665286
tg15
Tg(APPswe,PSEN1dE9)85Dbo/0 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax MGI:5008418
tg16
Tg(APPswe,PSEN1dE9)85Dbo/0 D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo MGI:5701399
tg17
Tg(APPswe,PSEN1dE9)85Dbo/0 involves: C3H * C57BL/6 MGI:3837130
tg18
Tg(APPswe,PSEN1dE9)85Dbo/0 involves: C3H/HeJ * C57BL/6J MGI:3663751


Genotype
MGI:5692156
cn1
Allelic
Composition
Agrntm1Rwb/Agrntm1Rwb
Tg(APPswe,PSEN1dE9)85Dbo/?
Tg(Tek-cre)1Ywa/?
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Agrntm1Rwb mutation (0 available); any Agrn mutation (48 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
Tg(Tek-cre)1Ywa mutation (4 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• elevated Amyloid beta in females mice

homeostasis/metabolism
• elevated Amyloid beta in females mice




Genotype
MGI:5297909
cn2
Allelic
Composition
Map2k4tm1Ctr/Map2k4tm1Ctr
Map2k7tm1Rjd/Map2k7tm1Rjd
Tg(APPswe,PSEN1dE9)85Dbo/0
Tg(Camk2a-cre/ERT2)2Gsc/0
Genetic
Background
involves: C3H * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Map2k4tm1Ctr mutation (0 available); any Map2k4 mutation (21 available)
Map2k7tm1Rjd mutation (0 available); any Map2k7 mutation (9 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
Tg(Camk2a-cre/ERT2)2Gsc mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• tamoxifen-treated mice develop fewer plaques than control mice expressing Tg(APPswe,PSEN1dE9)85Dbo
• tamoxifen-treated mice exhibit fewer dystrophic neurite clusters and few isolated neurites with residual bodies compared with control mice expressing Tg(APPswe,PSEN1dE9)85Dbo

homeostasis/metabolism
• tamoxifen-treated mice develop fewer plaques than control mice expressing Tg(APPswe,PSEN1dE9)85Dbo




Genotype
MGI:5050418
cx3
Allelic
Composition
Prnptm2Edin/Prnptm2Edin
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
B6.Cg-Prnptm2Edin Tg(APPswe,PSEN1dE9)85Dbo
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Prnptm2Edin mutation (7 available); any Prnp mutation (96 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
N
• unlike transgenic mice wild-type for Prnp, life span is similar to wild-type in transgenic mice null for Prnp

behavior/neurological
N
• unlike transgenic mice wild-type for Prnp, spatial learning and passive avoidance behavior are similar to controls in transgenic mice null for Prnp

nervous system
N
• unlike transgenic mice wild-type for Prnp, axon degeneration and synapse loss are not seen in transgenic mice null for Prnp
• plaque burdens are minimally different from transgenic mice wild-type for Prnp
• astrogliosis is similar to transgenic mice wild-type for Prnp

homeostasis/metabolism
• plaque burdens are minimally different from transgenic mice wild-type for Prnp




Genotype
MGI:5702670
cx4
Allelic
Composition
Hc1/Hc1
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hc1 mutation (7 available); any Hc mutation (65 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• Background Sensitivity: the complement pathway does not impact plaque deposition in the cortex, the number of plaques is the same as that in transgene carriers with the DBA/2J allele of Hc

behavior/neurological
• Background Sensitivity: despite the presence of functional hemolytic complement these mice have the same rate of lethal seizures as transgenics with the non-functional DBA/2J allele

mortality/aging

nervous system
N
• no significant differences are found in cortical neuron number in complement deficient versus functional transgene carriers
• Background Sensitivity: despite the presence of functional hemolytic complement these mice have the same rate of lethal seizures as transgenics with the non-functional DBA/2J allele
• Background Sensitivity: the complement pathway does not impact plaque deposition in the cortex, the number of plaques is the same as that in transgene carriers with the DBA/2J allele of Hc




Genotype
MGI:3810993
cx5
Allelic
Composition
Itm2btm1.1Ldad/Itm2b+
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: 129 * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Itm2btm1.1Ldad mutation (0 available); any Itm2b mutation (9 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• obvious increase in soluble APP-alpha in brain homogenates
• significant increase in both Abeta40 and Abeta42 compared to mice wild-type for Itm2b




Genotype
MGI:5692159
cx6
Allelic
Composition
Agrntm5Jrs/Agrntm5Jrs
Tg(APPswe,PSEN1dE9)85Dbo/?
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Agrntm5Jrs mutation (0 available); any Agrn mutation (48 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
N
• Agrn gene is expressed primarily in CNS neurons
• no affect on amyloid beta




Genotype
MGI:4359165
cx7
Allelic
Composition
Nr1h3tm1Djm/Nr1h3tm1Djm
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: 129S6/SvEvTac * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nr1h3tm1Djm mutation (3 available); any Nr1h3 mutation (17 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• a significant increase in cortical the Abeta1-40 plaque number is seen in mice at 32 weeks of age compared transgenic mice on a wild-type background
• plaques are also increased in size

homeostasis/metabolism
• a significant increase in cortical the Abeta1-40 plaque number is seen in mice at 32 weeks of age compared transgenic mice on a wild-type background
• plaques are also increased in size




Genotype
MGI:4359167
cx8
Allelic
Composition
Nr1h2tm1Djm/Nr1h2tm1Djm
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: 129S6/SvEvTac * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nr1h2tm1Djm mutation (3 available); any Nr1h2 mutation (14 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• a significant increase in cortical the Abeta1-40 plaque number is seen in mice at 32 weeks of age compared transgenic mice on a wild-type background
• plaques are also increased in size
• there is also a significant increase in Abeta1-42 plaque number at this age

homeostasis/metabolism
• a significant increase in cortical the Abeta1-40 plaque number is seen in mice at 32 weeks of age compared transgenic mice on a wild-type background
• plaques are also increased in size
• there is also a significant increase in Abeta1-42 plaque number at this age




Genotype
MGI:4834862
cx9
Allelic
Composition
Ptger2tm1Brey/Ptger2tm1Brey
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: 129S6/SvEvTac * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptger2tm1Brey mutation (1 available); any Ptger2 mutation (19 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• at 12 months of age in males, indices of lipid peroxidation are reduced in the brain suggesting a decrease in oxidative stress relative to transgenic mice wild-type for Ptger2
• however, no difference is detected at 2 months of age prior to onset of plaque formation

homeostasis/metabolism
• at 8 and 12 months of age in females and males, respectively, the levels of Abeta peptides and the amyloid plaque load are reduced relative to transgenic mice wild-type for Ptger2




Genotype
MGI:5295743
cx10
Allelic
Composition
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pion)Pggd/Gt(ROSA)26Sor+
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: 129S6/SvEvTac * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pion)Pggd mutation (0 available); any Gt(ROSA)26Sor mutation (384 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• doxycycline-treated mice exhibit fewer amyloid plaques compared with un-induced mice

homeostasis/metabolism
• doxycycline-treated mice exhibit fewer amyloid plaques compared with un-induced mice




Genotype
MGI:5292071
cx11
Allelic
Composition
Rtn4rl2tm1Yanr/Rtn4rl2tm1Yanr
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: 129S6/SvEvTac * C3H * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Rtn4rl2tm1Yanr mutation (0 available); any Rtn4rl2 mutation (11 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• mice exhibit reduced amyloid plaque production compared to in Tg(APPswe,PSEN1dE9)85Dbo mice

homeostasis/metabolism
• mice exhibit reduced amyloid plaque production compared to in Tg(APPswe,PSEN1dE9)85Dbo mice




Genotype
MGI:5692162
cx12
Allelic
Composition
Tg(APPswe,PSEN1dE9)85Dbo/?
Tg(MGS1-19375/CFP)2R9Rwb/?
Genetic
Background
involves: C3H * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
Tg(MGS1-19375/CFP)2R9Rwb mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• decreased levels of both amyloid beta-40 and -42
• mostly insoluble forms are reduced
• decrease is significant in males but not females

homeostasis/metabolism
• decreased levels of both amyloid beta-40 and -42
• mostly insoluble forms are reduced
• decrease is significant in males but not females




Genotype
MGI:5435319
cx13
Allelic
Composition
Leprdb/Lepr+
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: C3H * C57BL/6 * C57BLKS/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Leprdb mutation (11 available); any Lepr mutation (74 available)
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• nonfasting blood glucose levels are elevated compared to control Leprdb heterozygotes
• however, fasting blood glucose is normal at 5-7 weeks of age
• nonfasting and fasting hyperinsulinemia
• elevation in nonfasting plasma cholesterol levels
• however, fasting cholesterol levels are normal
• mutants exhibit decreased insulin sensitivity
• mutants exhibit an increase in expression of amyloid beta protein in plasma compared to Leprdb heterozygotes, however they do not show amyloid beta plaques yet at 5-7 weeks of age

endocrine/exocrine glands
• increase in beta cell mass and beta cell area compared to control Leprdb heterozygotes

growth/size/body
N
• body weight is normal at 5-7 weeks of age




Genotype
MGI:3665286
tg14
Allelic
Composition
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• sparse deposits observed at 21 weeks of age, however, numerous deposits are observed at 45 and 60 weeks (J:113199)
• deposits are more extensive in females (J:113199)
• level of brain amyloid beta peptide 42 is predominant over 40; levels increase dramatically after 20 weeks of age (J:113199)
• senile plaques detected by thioflavin S or the anti-amyloid beta antibody, 3D6, as early as 4 months of age (J:113200)
• plaques are restricted to cortex and hippocampus at time points up to 12 months of age (J:113200)
• plaques increase in number and size over time (J:113200)
• exhibits an overall increase in soluble and insoluble amyloid beta peptide 40 and 42 between 4 and 12 months (J:113200)
• insoluble amyloid beta42 is increased 2-fold in cerebrum of sucrose-fed mice as compared to water-fed control (J:129021)
• total amyloid beta levels are increased by 3.6 fold in sucrose fed mice (J:129021)
• amyloid beta deposition is increased by 2.9-fold as determined by immunohistochemical and morphometric analysis in sucrose-fed mice (J:129021)
• exhibits progressive increase in cerebral amyloid angiopathy as early as 6 months
• amyloid deposition is observed in leptomeningeal vasculature

behavior/neurological
• transgenic mice fed sucrose water failed to learn Morris water maze test after 5 days of training
• water-fed transgenic mice retained some learning ability over 5 day test period, but did not perform as well in the water maze test as non-transgenic controls
• mice fed sucrose water exhibited increased water consumption

homeostasis/metabolism
• fasting plasma insulin levels are increased 3 fold in mice fed sucrose water as compared to water-fed control
• total cholesterol, but not HDL, levels are increased 30% in mice fed sucrose water as compared to water-fed control
• elevated plasma triglyceride levels observed in females at 15 weeks of age
• mice fed sucrose water displayed an impaired glucose tolerance as compared to water-fed control
• sparse deposits observed at 21 weeks of age, however, numerous deposits are observed at 45 and 60 weeks (J:113199)
• deposits are more extensive in females (J:113199)
• level of brain amyloid beta peptide 42 is predominant over 40; levels increase dramatically after 20 weeks of age (J:113199)
• senile plaques detected by thioflavin S or the anti-amyloid beta antibody, 3D6, as early as 4 months of age (J:113200)
• plaques are restricted to cortex and hippocampus at time points up to 12 months of age (J:113200)
• plaques increase in number and size over time (J:113200)
• exhibits an overall increase in soluble and insoluble amyloid beta peptide 40 and 42 between 4 and 12 months (J:113200)
• insoluble amyloid beta42 is increased 2-fold in cerebrum of sucrose-fed mice as compared to water-fed control (J:129021)
• total amyloid beta levels are increased by 3.6 fold in sucrose fed mice (J:129021)
• amyloid beta deposition is increased by 2.9-fold as determined by immunohistochemical and morphometric analysis in sucrose-fed mice (J:129021)
• exhibits progressive increase in cerebral amyloid angiopathy as early as 6 months
• amyloid deposition is observed in leptomeningeal vasculature

cardiovascular system

growth/size/body
• mice fed sucrose water consistently gained weight over study time period (2 months- 8 months)
• sucrose-fed mice increased body weight by 17% over water-fed controls




Genotype
MGI:5008418
tg15
Allelic
Composition
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• about 40% of mice are lost by 12 months of age

behavior/neurological
• mice exhibit decreased freezing to context
• 4 month old mice infused with the specific PTEN inhibitor VO-OHpic into the brain ventricles over a period for 3-4 weeks show improvement in contextual conditioning behavior
• 4 month old mice infused with a cell-permeable PTEN-PDZ peptide over a period of 3-4 weeks into the brain ventricles show improvement in the contextual fear conditioning tests
• however, VO-OHpic treatment does not affect auditory-cued fear conditioning (hippocampal-independent task), exploratory activity or basal freezing behavior
• severely impaired performance in a morris water maze with much longer latencies to reach a hidden platform (J:160557)
• performance in a morris water maze declines between 3 and 12 months of age (J:160557)
• 6 month old mutants exhibit slower visuospatial learning than control mice (J:172426)
• in the visuospatial re-learning test performed at 9, 11, 13, 15, and 18 months of age, mutants exhibit a decrease in the speed of re-learning the task compared to controls (J:172426)
• mice exhibit impaired behavior in the novel object location task
• 4 month old mice infused with the specific PTEN inhibitor VO-OHpic into the brain ventricles over a period for 3-4 weeks show improvement in spatial learning tasks
• 4 month old mice infused with a cell-permeable PTEN-PDZ peptide over a period of 3-4 weeks into the brain ventricles show improvement in the novel object-location task
• Background Sensitivity: premature death early in life eappears to result from convulsive seizures and is much less frequent on the C57BL/6J background than on the DBA/2J background

nervous system
• Background Sensitivity: premature death early in life eappears to result from convulsive seizures and is much less frequent on the C57BL/6J background than on the DBA/2J background
• Background Sensitivity: there are more ThioS+ plaques in the cortex on the C57BL/6J background than on the DBA/2J background (J:227541)
• at 2 months of age carriers are indistinguishable from C57BL/6J controls, but at 4 months of age very small plaques are found in the cortex, and at 6 months of age plaques are evident in the cortex and hippocampus (J:208080)
• axon degeneration and synapse loss
• basal synaptic transmission is lower in hippocampal slices
• VO-OHpic treatment does not rescue the lower basal synaptic transmission
• semi-chronic treatment with VO-OHpic fully rescues LTP levels in hippocampal slices

taste/olfaction
N
• mutants do not exhibit Alzheimer's disease-related impairments in olfactory performance in tests based on an operant conditioning procedure and in tests based on a habituation/dishabituation procedure

homeostasis/metabolism
• Background Sensitivity: there are more ThioS+ plaques in the cortex on the C57BL/6J background than on the DBA/2J background (J:227541)
• at 2 months of age carriers are indistinguishable from C57BL/6J controls, but at 4 months of age very small plaques are found in the cortex, and at 6 months of age plaques are evident in the cortex and hippocampus (J:208080)

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Alzheimer's disease DOID:10652 OMIM:104300
OMIM:502500
OMIM:604154
OMIM:608907
J:160557 , J:172426 , J:234430




Genotype
MGI:5701399
tg16
Allelic
Composition
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• Background Sensitivity: although hemizygotes do have some ThioS+ plaque deposition in the cortex, there are far fewer plaques than are found in hemizygotes on the C57BL/6J background (average 10 per section versus 58 per section)

hematopoietic system
• cortical staining finds a slight increase in microglia in hemizygotes compared with DBA/2J controls

mortality/aging
• Background Sensitivity: There is a much higher rate of premature death in hemizygotes on the DBA/2J background than on the C57BL/6J background, although hemizygotes that survive beyond 6 months of age do not have a high rate of premature death thereafter

immune system
• cortical staining finds a slight increase in microglia in hemizygotes compared with DBA/2J controls

behavior/neurological
• Background Sensitivity: on the DBA/2J background hemizygotes that die prematurely are found in a lethal seizure pose of clenched front limbs and stretched out hind limbs consistent with the audiogenic seizure-induced death inherent in DBA/2J, but the percentage of hemizygotes found dead is much higher than that in wild type DBA/2J. Consistent with wild-type DBA/2J lethal seizures, premature death is not found in hemizygotes that survive beyond 6 months of age.
• despite the increased lethal seizures, the electroconvulsive threshold is not decreased relative to DBA/2J controls

nervous system
N
• no significant differences are found between hemizygotes and DBA/2J in neuron number in the three different regions of the cortex at 6 months of age, indicating no increase in neuronal cell loss, and the number of cortical astrocytes is normal
• Background Sensitivity: on the DBA/2J background hemizygotes that die prematurely are found in a lethal seizure pose of clenched front limbs and stretched out hind limbs consistent with the audiogenic seizure-induced death inherent in DBA/2J, but the percentage of hemizygotes found dead is much higher than that in wild type DBA/2J. Consistent with wild-type DBA/2J lethal seizures, premature death is not found in hemizygotes that survive beyond 6 months of age.
• despite the increased lethal seizures, the electroconvulsive threshold is not decreased relative to DBA/2J controls
• cortical staining finds a slight increase in microglia in hemizygotes compared with DBA/2J controls
• Background Sensitivity: although hemizygotes do have some ThioS+ plaque deposition in the cortex, there are far fewer plaques than are found in hemizygotes on the C57BL/6J background (average 10 per section versus 58 per section)

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Alzheimer's disease DOID:10652 OMIM:104300
OMIM:502500
OMIM:604154
OMIM:608907
J:227541




Genotype
MGI:3837130
tg17
Allelic
Composition
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
N
• striatal volume is similar in both transgenic and wild-type at either 6 or 12 months of age
• nuclei of medium spiny stellate neurons in both 6 and 12 month old transgenics are smaller and darker than wild-type
• numbers of neurons are reduced in striatum of 12, but not 6, month old transgenics
• numbers of neurons are reduced in striatum of 12, but not 6, month old transgenics
• reduced neuron density is observed in striatum of 12, but not 6, month old transgenics

homeostasis/metabolism
N
• mutants exhibit normal body weight, blood glucose, plasma insulin levels, nonfasting blood glucose and nonfasting plasma insulin, and normal glucose and insulin tolerance, indicating normal glucose homeostasis and insulin sensitivity
• increase in circulating amyloid beta protein levels




Genotype
MGI:3663751
tg18
Allelic
Composition
Tg(APPswe,PSEN1dE9)85Dbo/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(APPswe,PSEN1dE9)85Dbo mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• plaques are abundant in hippocampus and cortex by 9 months of age (J:87691)
• occasional deposits can be found in mice as young as 6 months of age (J:87691)
• ratio of amyloid beta peptide 40:42 is 0.50:1 (J:87691)
• deposits observed in hippocampus by 6 months of age (J:139071)
• transient long term potentiation (t-LTP) is reduced in transgenics and is age-independent

behavior/neurological
• transgenic mice exhibit a 4-5% higher preference for the arm of the radial arm water maze that held the platform on the previous day
• 13 month old transgenic mice commit more errors in the water maze than controls, at 7 months of age both groups test similarly
• 14 month old transgenic mice exhibit a reduced ability to maintain balance on a rotarod

growth/size/body
• at 14 months, transgenics weigh less than controls

homeostasis/metabolism
• plaques are abundant in hippocampus and cortex by 9 months of age (J:87691)
• occasional deposits can be found in mice as young as 6 months of age (J:87691)
• ratio of amyloid beta peptide 40:42 is 0.50:1 (J:87691)
• deposits observed in hippocampus by 6 months of age (J:139071)





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
09/12/2017
MGI 6.10
The Jackson Laboratory